Idarubicine
B Cell Lymphomas
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyPhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 59/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the B Cell Lymphomas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
azd6738 AstraZeneca | Phase 1 | CC |
CART22-65s University of Pennsylvania | Phase 1 | CC |
Cart22 Cells University of Pennsylvania | Phase 1 | CC |
Actr T Cell Product Cogent Biosciences, Inc. | D |
Same molecule, other indications
Idarubicine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →